Trial · NCT00055237
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
NCT00055237, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2012-07-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients. Trials, record NCT00055237. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00055237
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
- NCT number
- NCT00055237
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 19 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Kaposi's Sarcoma, HIV Infections, HIV Seronegativity
- Interventions
- Bevacizumab
- First posted
- 2003-02-21
- Last updated
- 2017-09-06
- Results first posted
- 2012-07-26
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response Rate | 36 months | Percentage of participants with a complete response (CR) + partial response (PR)per the Modified AIDS Clinical Trial Group Criteria (ACTG) for HIV-KS. PR is a 50% decrease in the number and/or size of previously existing lesions for 4 weeks; or complete flattening of at least 50% of all previously raised lesions lasting for at least 4 weeks; or a 50% decrease in the sum of the products of the largest perpendicular diameters of the marker lesions lasting for at least 4 weeks; CR is the absence of any detectable residual disease, including tumor associated edema, persisting for at least 4 weeks. |
| Secondary | Number of Participants With Adverse Events | 70 months | Here are the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response Rate | 36 months | Cohort 2 is not reported here because response rate in HIV negative patients was a secondary outcome. | Percentage of participants | MEAN |
| SECONDARY | Number of Participants With Adverse Events | 70 months | All adverse events regardless of attribution, over 202 cycles in 19 patients. Per protocol analysis of adverse events.~Cohort 1 and 2 are reported together. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rate | Cohort 1: Cohort 1: Pts With HIV-associated Kaposi's Sarcoma | 31 | 95% Confidence Interval 11 to 58.7 | Percentage of participants | |
| Number of Participants With Adverse Events | Cohort 1 & 2: Pts With HIV-associated and Classic KS | 19 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cohort 1: Cohort 1: Pts With HIV-associated Kaposi's Sarcoma | 17 | |
| Overall Study | STARTED | Cohort 2: Pts With Classic Kaposi's Sarcoma (HIV-uninfected) | 2 | |
| Overall Study | COMPLETED | Cohort 1: Cohort 1: Pts With HIV-associated Kaposi's Sarcoma | 17 | |
| Overall Study | COMPLETED | Cohort 2: Pts With Classic Kaposi's Sarcoma (HIV-uninfected) | 2 | |
| Overall Study | NOT COMPLETED | Cohort 1: Cohort 1: Pts With HIV-associated Kaposi's Sarcoma | 0 | |
| Overall Study | NOT COMPLETED | Cohort 2: Pts With Classic Kaposi's Sarcoma (HIV-uninfected) | 0 |
Source ClinicalTrials.gov
Adverse events106
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain or cramping | Gastrointestinal disorders | Cohort 1 & 2: Pts With HIV-associated and Classic KS | 1 | 19 | 1 |
| other | Alkaline phosphatase | Investigations | Cohort 1 & 2: Pts With HIV-associated and Classic KS | 2 | 19 | 8 |
| other | Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip) | Immune system disorders | Cohort 1 & 2: Pts With HIV-associated and Classic KS | 8 | 19 | 10 |
| other | Amylase | Investigations | Cohort 1 & 2: Pts With HIV-associated and Classic KS | 9 | 19 | 20 |
| other | Anorexia | Gastrointestinal disorders | Cohort 1 & 2: Pts With HIV-associated and Classic KS | 2 | 19 | 2 |
| other | Bilirubin | Investigations | Cohort 1 & 2: Pts With HIV-associated and Classic KS | 11 | 19 | 26 |
| other | CPK (creatine phosphokinase) | Investigations | Cohort 1 & 2: Pts With HIV-associated and Classic KS | 8 | 19 | 27 |
| other | Constipation | Gastrointestinal disorders | Cohort 1 & 2: Pts With HIV-associated and Classic KS | 5 | 19 | 6 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Cohort 1 & 2: Pts With HIV-associated and Classic KS | 9 | 19 | 15 |
| other | Creatinine | Investigations | Cohort 1 & 2: Pts With HIV-associated and Classic KS | 3 | 19 | 6 |
1 to 10 of 106Source ClinicalTrials.gov
See all 106 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cohort 1 & 2: Pts With HIV-associated and Classic KS | 0 | 19 |
| Total, other adverse events | Cohort 1 & 2: Pts With HIV-associated and Classic KS | 19 | 19 |
| Total, serious adverse events | Cohort 1 & 2: Pts With HIV-associated and Classic KS | 4 | 19 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22430271 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00055237
GET https://conductscience.org/api/trials/v1/NCT00055237/events?page=2